Alnylam Pharmaceuticals, Inc. share price logo

Alnylam Pharmaceuticals, Inc. Share Price

NASDAQ: ALNY

Large Cap

$312.20

+1.10

(+0.35%)

as on

Alnylam Pharmaceuticals, Inc. Stock Performance

as on March 21, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $311.66
    $322.43
    downward going graph

    0.17%

    Downside

    3.28%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $205.87
    $495.55
    downward going graph

    34.06%

    Downside

    58.73%

    Upside

    downward going graph

Alnylam Pharmaceuticals, Inc. share price movements today

Previous Close
$311.10
Open
$313.69
Volume
1.1M
Day's Low - High
$311.66 - $322.43
52 Week Low - High
$205.87 - $495.55

Alnylam Pharmaceuticals, Inc. Historical Returns

1 Month Return
-7.14 %
3 Month Return
-22 %
1 Year Return
+ 10.18 %
3 Year Return
+ 63.93 %
5 Year Return
+ 116.54 %

Alnylam Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators

Check Alnylam Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$41.3B

EPS (TTM)

9.4313

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

133.52

Industry PE ratio

17.63179487179487

PEG Ratio

-0.49

EBITDA

557.2M

Revenue (TTM)

3.7B

Profit Margin

8.45%

Return On Equity TTM

73.28%

Alnylam Pharmaceuticals, Inc. Stock Valuation

Track how Alnylam Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.

Alnylam Pharmaceuticals, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-115.71x)

September 30, 2024

Industry (17.63x)

March 21, 2026

Today (133.52x)

March 21, 2026

Highest (166.89x)

September 30, 2025

LowHigh

Today’s Price to Earnings Ratio: 133.52x

Alnylam Pharmaceuticals, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Alnylam Pharmaceuticals, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.3B116.54%133.528.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$116.3B110.08%29.9432.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$32.5BNA114.935.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$78.0B54.71%17.831.41%

Stock Returns calculator for Alnylam Pharmaceuticals, Inc. Stock including INR - Dollar returns

The Alnylam Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Alnylam Pharmaceuticals, Inc. investment value today

Current value as on today

₹1,19,090

Returns

₹19,090

(+19.09%)

Returns from Alnylam Pharmaceuticals, Inc. Stock

₹10,186 (+10.19%)

Dollar Returns*

₹8,904 (+8.9%)

Analyst Recommendation on Alnylam Pharmaceuticals, Inc. Stock

Based on 34 analysts

BUY

70.59%

Buy

29.41%

Hold

0.00%

Sell

Based on 34 analysts, 70.59% of analysts recommend a 'BUY' rating for Alnylam Pharmaceuticals, Inc.. Average target price of $449.32

Alnylam Pharmaceuticals, Inc. Share Price Target

Get share price movements and forecasts by analysts on Alnylam Pharmaceuticals, Inc..

What analysts predicted

30.52%UPSIDE

Target Price

$449.32

Current Price

$312.2

Analyzed by

34 Analysts

Target

$449.32

Alnylam Pharmaceuticals, Inc. target price $449.32, a slight upside of 30.52% compared to current price of $312.2. According to 34 analysts rating.

Alnylam Pharmaceuticals, Inc. Stock’s Investor Sentiment and Interest

Search interest for Alnylam Pharmaceuticals, Inc. Stock has decreased by -1% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-1% versus previous 30 day period

Alnylam Pharmaceuticals, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
750
439
494
659
500
593
594
773
1,249
1,097
Gross Profit
666
353
428
591
415
490
523
630
1,051
829
Operating Income
213
-116
-43
48
-76
-105
18
-16
367
131
EBITDA
194
-92
-14
37
-60
-140
11
18
297
145
Interest Expense
30
31
35
33
34
38
38
40
44
129
Depreciation
23
23
25
24
27
-20
14
13
13
13
Income Before Tax
150
-137
-63
-11
-108
-193
-41
-35
238
161
Income Tax Expense
2
0
2
5
2
-110
15
30
-12
-25
Net Income
147
-137
-65
-16
-111
-83
-57
-66
251
186
Net Profit Margin
19.69%
-31.35%
-13.34%
-2.56%
-22.27%
-14.12%
-9.67%
-8.57%
20.10%
16.99%

Alnylam Pharmaceuticals, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
47
89
74
219
492
844
1,037
1,828
2,248
3,713
Gross Profit
47
89
73
194
414
704
868
1,517
1,924
3,036
Operating Income
-424
-500
-814
-939
-828
-708
-785
-282
-176
501
EBITDA
-409
-486
-754
-885
-736
-661
-926
-258
-178
557
Interest Expense
8
12
29
108
84
143
155
121
141
252
Depreciation
-
13
6
54
74
89
85
97
56
55
Income Before Tax
-410
-490
-760
-885
-855
-852
-1,126
-433
-377
323
Income Tax Expense
-23
-25
0
0
2
0
4
6
-99
9
Net Income
-410
-490
-761
-886
-858
-852
-1,131
-440
-278
313
Net Profit Margin
-869.63%
-545.95%
-1016.58%
-403.24%
-174.15%
-101.01%
-109.04%
-24.08%
-12.37%
8.45%

Alnylam Pharmaceuticals, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-137
-65
-16
-111
-83
-57
-66
251
186
Operating Cash Flow
-29
-81
124
43
-94
-118
153
325
163
Investing Cash Flow
-240
-67
33
-30
-52
113
-141
501
-37
Financing Cash Flow
39
28
131
102
30
44
53
-448
45
Change in Cash
-220
-130
286
131
-133
53
93
376
166

Alnylam Pharmaceuticals, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-490
-761
-886
-858
-852
-1,131
-440
-278
313
Operating Cash Flow
-382
-562
-278
-614
-641
-541
104
-8
524
Investing Cash Flow
-290
272
-417
-435
-273
169
-336
-116
436
Financing Cash Flow
1,124
65
823
994
1,247
425
172
294
-305
Change in Cash
451
-224
126
-50
323
46
-53
153
690

Mutual Funds that own Alnylam Pharmaceuticals, Inc. Stock

Check out the Mutual Funds with significant holdings in Alnylam Pharmaceuticals, Inc..

Funds
Holdings
Shares Held
ICICI Prudential NASDAQ 100 Index Fund Direct Growth
ICICI Prudential NASDAQ 100 Index Fund Direct Growth
0.23622%
2185

Global Institutional Holdings in Alnylam Pharmaceuticals, Inc.

Funds
Holdings
State Street Corp
2.32%
Winslow Capital Management, LLC
0.9%
Dodge & Cox
1.48%
Amvescap Plc.
1.12%
Capital Research Global Investors
5.45%
See all

Alnylam Pharmaceuticals, Inc. News & Key Events

  • img

    Today's Timeline - 18 February

    Wed, 08:31 PM

    -

    Yvonne Greenstreet, CEO, sold 6,958 shares of Alnylam Pharmaceuticals for $2.16M, indicating insider selling activity.

Insights on Alnylam Pharmaceuticals, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ALNY has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 11.3% return, outperforming this stock by 1.1%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Alnylam Pharmaceuticals, Inc. has seen a decline in its net profit for the last two quarters. The net profit decreased from $251.08 million to $186.41 million, resulting in an average decrease of 25.8% per quarter.

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Alnylam Pharmaceuticals, Inc. has experienced a decline in revenue over the last two quarters. Their revenue fell from $1.24 billion to $1.09 billion, which represents an average decrease of 12.2% each quarter.

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, ALNY stock has moved down by -22.0%

About Alnylam Pharmaceuticals, Inc.

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
OrganisationAlnylam Pharmaceuticals, Inc.
Headquarters675 West Kendall Street, Cambridge, MA, United States, 02142
IndustryHealth Technology
CEODr. Yvonne L. Greenstreet M.B.A., M.D.
E-voting on sharesClick here to vote

Key Management of Alnylam Pharmaceuticals, Inc.

Name

Title

Dr. Yvonne L. Greenstreet M.B.A., M.D.

CEO & Director

Dr. Kevin Joseph Fitzgerald Ph.D.

Executive VP, Chief Scientific Officer and Head of Early Research & Early Development

Dr. Pushkal P. Garg M.D.

Chief Research & Development Officer

Mr. Tolga Tanguler M.B.A.

Executive VP & Chief Commercial Officer

Mr. Piyush Sharma J.D.

Chief Ethics & Compliance Officer

Mr. Bryan Andrew Supran J.D.

Chief Legal Officer

Ms. Christine Regan Akinc

Chief Corporate Communications Officer

Dr. Phillip A. Sharp Ph.D.

Co-Founder, Member of the Scientific Advisory Board

Mr. Jeffrey V. Poulton M.B.A.

CFO & Executive VP

Mr. Timothy J. Maines

Chief Technical Operations & Quality Officer

FAQs

What is Alnylam Pharmaceuticals, Inc. share price today?

Alnylam Pharmaceuticals, Inc. share price today is $312.2 as on at the close of the market. Alnylam Pharmaceuticals, Inc. share today touched a day high of $322.43 and a low of $311.66.

What is the 52 week high and 52 week low for Alnylam Pharmaceuticals, Inc. share?

Alnylam Pharmaceuticals, Inc. share touched a 52 week high of $495.55 on and a 52 week low of $205.87 on . Alnylam Pharmaceuticals, Inc. stock price today i.e. is closed at $312.2,which is 37.00% down from its 52 week high and 51.65% up from its 52 week low.

What is Alnylam Pharmaceuticals, Inc.'s market capitalisation today?

Alnylam Pharmaceuticals, Inc. market capitalisation is $0.04T as on .

How to invest in Alnylam Pharmaceuticals, Inc. Stock (ALNY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Alnylam Pharmaceuticals, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Alnylam Pharmaceuticals, Inc. Shares that will get you 0.0048 shares as per Alnylam Pharmaceuticals, Inc. share price of $312.2 per share as on March 21, 2026 at 1:29 am IST.

What is the minimum amount required to buy Alnylam Pharmaceuticals, Inc. Stock (ALNY) from India?

Indian investors can start investing in Alnylam Pharmaceuticals, Inc. (ALNY) shares with as little as ₹93.652 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹936.52 in Alnylam Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Alnylam Pharmaceuticals, Inc. share’s latest price of $312.2 as on March 21, 2026 at 1:29 am IST, you will get 0.0320 shares of Alnylam Pharmaceuticals, Inc.. Learn more about fractional shares .

What are the returns that Alnylam Pharmaceuticals, Inc. has given to Indian investors in the last 5 years?

Alnylam Pharmaceuticals, Inc. stock has given 116.54% share price returns and 28.67% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?